Sol-Gel Announces Pricing of Public Offering of Ordinary Shares
Gross proceeds from the sale of the ordinary shares, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately
The Company intends to use the net proceeds from the offering for pre-commercialization activities for Epsolay® and TWIN and the remainder for working capital and other general corporate purposes.
The offering is being made only by means of a prospectus. A shelf registration statement was previously filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These statements are based on information currently available to the Company or the Company’s current beliefs and expectations, including the Company’s statements regarding the completion, timing and size of the offering of ordinary shares, and the use of proceeds therefrom, which are subject to risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the offering. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to changes in the Company’s expectations or events or circumstances occurring after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in the Company’s periodic reports filed with the
|For further information:|
|Sol-Gel Contact:||U.S. Investor Contact:||Media Contact:|
|Gilad Mamlok||Chiara Russo||Stephanie Bukantz|
|Chief Financial Officer||Solebury Trout||Chamberlain Healthcare PR|
Source: Sol-Gel Technologies Ltd.